Logo

Cytokinetics Closes $20M Round of Financing, Adds New Board Members

Sep 24, 1999
Premium

SOUTH SAN FRANCISCO, Calif.--Cytokinetics, a privately held biotechnology and informatics company here that is developing a cellular bioinformatics database based on cytoskeletal pharmacology, announced that it has completed a $20 million Series B Preferred Stock financing round. Investors included International Biomedicine Holdings, Microsoft co-founder Paul Allen's Vulcan Ventures, Duke University, and New Medical Technologies, Mayfield Fund, and Sevin Rosen Funds. Along with the funding, the company has added William Rutter, founder and former chairman of Chiron, and Stefan Ryser, partner of International Biomedicine Management Partners, to its board of directors.

Filed under

Informatics
Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.